These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22996593)

  • 1. Exploring the selectivity of a ligand complex with CDK2/CDK1: a molecular dynamics simulation approach.
    Tripathi SK; Singh SK; Singh P; Chellaperumal P; Reddy KK; Selvaraj C
    J Mol Recognit; 2012 Oct; 25(10):504-12. PubMed ID: 22996593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of a ligand complexed with Cdk2/Cdk4 by computer simulation.
    Jiang Y; Zou J; Gui C
    J Mol Model; 2005 Nov; 11(6):509-15. PubMed ID: 15928920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases.
    Braña MF; Cacho M; García ML; Mayoral EP; López B; de Pascual-Teresa B; Ramos A; Acero N; Llinares F; Muñoz-Mingarro D; Lozach O; Meijer L
    J Med Chem; 2005 Nov; 48(22):6843-54. PubMed ID: 16250643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
    Chohan TA; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors.
    Lee J; Kim KH; Jeong S
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4203-5. PubMed ID: 21684737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of 2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as Aurora kinases inhibitors.
    Le Brazidec JY; Pasis A; Tam B; Boykin C; Wang D; Marcotte DJ; Claassen G; Chong JH; Chao J; Fan J; Nguyen K; Silvian L; Ling L; Zhang L; Choi M; Teng M; Pathan N; Zhao S; Li T; Taveras A
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4033-7. PubMed ID: 22607669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of in silico models for pyrazoles and pyrimidine derivatives as cyclin-dependent kinase 2 inhibitors.
    Wang F; Ma Z; Li Y; Zhu S; Xiao Z; Zhang H; Wang Y
    J Mol Graph Model; 2011 Sep; 30():67-81. PubMed ID: 21763166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors.
    Tripathi SK; Muttineni R; Singh SK
    J Theor Biol; 2013 Oct; 334():87-100. PubMed ID: 23727278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An integrated chemical biology approach provides insight into Cdk2 functional redundancy and inhibitor sensitivity.
    Echalier A; Cot E; Camasses A; Hodimont E; Hoh F; Jay P; Sheinerman F; Krasinska L; Fisher D
    Chem Biol; 2012 Aug; 19(8):1028-40. PubMed ID: 22921070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
    Wood DJ; Korolchuk S; Tatum NJ; Wang LZ; Endicott JA; Noble MEM; Martin MP
    Cell Chem Biol; 2019 Jan; 26(1):121-130.e5. PubMed ID: 30472117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
    Mou J; Chen D; Deng Y
    Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular models of cyclin-dependent kinase 1 complexed with inhibitors.
    Canduri F; Uchoa HB; de Azevedo WF
    Biochem Biophys Res Commun; 2004 Nov; 324(2):661-6. PubMed ID: 15474478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
    Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
    Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
    Park H; Yeom MS; Lee S
    Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
    Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free-energy-based methods for binding profile determination in a congeneric series of CDK2 inhibitors.
    Fidelak J; Juraszek J; Branduardi D; Bianciotto M; Gervasio FL
    J Phys Chem B; 2010 Jul; 114(29):9516-24. PubMed ID: 20593892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances on structure-informed drug discovery of cyclin-dependent kinase-2 inhibitors.
    Duca JS
    Future Med Chem; 2009 Nov; 1(8):1453-66. PubMed ID: 21426059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.